Gyre Therapeutics (GYRE) FCF Margin (2010 - 2026)
Gyre Therapeutics (GYRE) reported FCF Margin of 13.42% for Q1 2026, up 1456.0% year-over-year from 0.86% in Q1 2025, and up 186.9% on a QoQ basis from 15.44% in Q4 2025.
Gyre Therapeutics (GYRE) has 16 years of FCF Margin data on file, last reported at 13.42% in Q1 2026.
- Quarterly FCF Margin rose 1456.0% year-over-year to 13.42% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2.63% (up 1144.0% YoY) and the FY2025 annual result came in at 0.16%, up 547.0% from the prior year.
- FCF Margin improved to 13.42% in Q1 2026 per GYRE's latest filing, from 15.44% in the prior quarter.
- Across five years, FCF Margin topped out at 41.67% in Q4 2022 and bottomed at 1517.63% in Q1 2022.
- The 5-year median for FCF Margin is 7.0% (2025), against an average of 94.64%.
- Peak annual rise in FCF Margin reached 155243 bps in 2023, while the deepest fall reached 3786 bps in 2023.
- Tracing GYRE's FCF Margin over 5 years: stood at 41.67% in 2022, then plunged by 91 bps to 3.82% in 2023, then slumped by 353 bps to 9.66% in 2024, then sank by 60 bps to 15.44% in 2025, then soared by 187 bps to 13.42% in 2026.
- Per Business Quant, the three latest GYRE FCF Margin figures stand at 13.42% (Q1 2026), 15.44% (Q4 2025), and 12.86% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 13.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.42% |
| Dec 31, 2025 | -15.44% |
| Sep 30, 2025 | 12.86% |
| Jun 30, 2025 | 7.00% |
| Mar 31, 2025 | -1.14% |
| Dec 31, 2024 | -9.66% |
| Sep 30, 2024 | 4.05% |
| Jun 30, 2024 | -27.55% |
| Mar 31, 2024 | 9.76% |
| Dec 31, 2023 | 3.82% |
| Sep 30, 2023 | 17.50% |
| Jun 30, 2023 | 7.01% |
| Mar 31, 2023 | 34.80% |
| Dec 31, 2022 | 41.67% |
| Mar 31, 2022 | -1,517.63% |
| Dec 31, 2021 | -724.43% |
| Sep 30, 2021 | -960.94% |
| Jun 30, 2021 | -1,777.65% |
| Mar 31, 2021 | -1,660.26% |
| Dec 31, 2020 | -1,088.82% |
| Sep 30, 2020 | -1,478.50% |
| Jun 30, 2020 | -913.87% |
| Mar 31, 2020 | -29.37% |
| Mar 31, 2018 | -88,416.67% |
| Dec 31, 2017 | -1,992.77% |
| Sep 30, 2017 | -1,550.00% |
| Jun 30, 2017 | -3,965.77% |
| Mar 31, 2017 | -1,584.87% |
| Dec 31, 2016 | -7,181.69% |
| Sep 30, 2016 | -4,707.34% |
| Jun 30, 2016 | -3,556.88% |
| Mar 31, 2016 | -4,433.94% |
| Dec 31, 2015 | -4,807.34% |
| Sep 30, 2015 | -8,833.94% |
| Jun 30, 2015 | -159.14% |
| Mar 31, 2015 | -443.45% |
| Dec 31, 2014 | -306.40% |
| Sep 30, 2014 | 3,551.92% |
| Jun 30, 2014 | -3,001.01% |
| Mar 31, 2014 | -4,998.65% |
| Dec 31, 2013 | 24,968.82% |
| Mar 31, 2013 | -265.55% |
| Dec 31, 2012 | -1,999.32% |
| Sep 30, 2012 | -1,354.69% |
| Jun 30, 2012 | -51.79% |
| Mar 31, 2012 | -109.14% |
| Dec 31, 2011 | -109.69% |
| Sep 30, 2011 | -96.27% |
| Jun 30, 2011 | -113.18% |
| Mar 31, 2011 | -58.07% |
| Dec 31, 2010 | -79.02% |
| Sep 30, 2010 | -12,636.03% |